about
An integrated psychological strategy for advanced colorectal cancer patientsDifferential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsOutcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working groupDocetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphomaAssessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience.A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 studyBaseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method.Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.Laser-assisted hatching of human embryos: may two alternative approaches (thinning versus drilling) impact on implant rate?Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingImmunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma.Aromatase inhibitors in post-menopausal metastatic breast carcinoma.Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients.
P50
Q21245616-4D70DA15-A3DA-44FC-8A0D-40AD9CA550F4Q27853176-1D810D6C-77ED-4B0D-A9FE-F163059BE774Q33273672-09747F99-E4C3-403A-BC1B-578F70F21BB0Q33366769-88BAF962-B725-44FC-9F5F-1DE095F792E7Q33367641-439DC905-E463-4BB3-8FBD-BABA7882253FQ33396809-E1706814-7E41-400A-A778-1356B5946172Q33402830-E9EB3631-3AD7-4CD2-9260-6568FC8CCED2Q33424731-B6BA7F89-52CD-4748-90A0-519979342DDAQ33625227-62F52025-07B3-4D82-BEA2-E5B28F86D8F7Q33643902-B8EB487A-ED75-411E-A0A6-D90FF74E77A1Q33707448-60E3AE81-8D7F-48AC-B823-AC948E4D65AFQ33766974-C8522BE6-1028-4FCA-8FA8-7D6A798523E2Q33930593-3F455E69-D123-42DC-87A4-FF9AFED01B3AQ33933669-47E709EC-C985-4352-89F2-69207A2EBE37Q34240305-44E15C1A-B783-4C26-9E20-F08BD84C8A6FQ34452673-EA2A5484-E7DB-49D8-8CA4-46D796E5C56BQ34543041-ADD08973-BF94-4501-B0EC-45B32EB3D0F5Q34658209-67F37239-D4CD-431C-8597-E333337A98CFQ34855129-9DE039E5-4B40-46A0-945B-2EC440C8AB35Q35061280-BB188780-DCE2-4FA2-8C79-ABE6C9C979F9Q35241042-31AD40C0-D419-413D-856C-50ADF6674F6AQ35450437-6F78D42D-1FE0-4474-B441-4C7565DCC2F4Q35786490-374283AA-EE22-481F-8E71-A579450EE726Q35798996-00AD3081-F9F2-4ADA-981E-4E942BA8DB6CQ35950753-78E43D1B-AE0F-4F90-B8C4-D98ED9CDED9CQ35976841-DD64B2DC-9E9F-4D25-9975-D4543952E9A8Q35994850-908153AC-7B41-4F25-94E2-5B1CDCF7C5A6Q36086834-89944A3F-CEBC-4FD9-B99D-5ADCD69372BFQ36223219-07C927C9-D451-460B-B913-B3E459AB346FQ36246377-B6B4D3B4-EFDC-4889-BB0F-9470C0E4F34EQ36298852-15FA9FE5-C26E-43FD-8432-9C86191FD2D2Q36326026-FB2AD7FF-ABFF-458A-A3EB-116B1F9940F4Q36382293-4A02EC6F-DFE3-4232-B257-239273A56130Q36614435-EF905051-A2C2-4AA7-B3D4-1720D52F0DBFQ36673469-728F4EB4-4273-4C50-81CB-B7F6CF86402FQ36711007-E53BB123-094F-4D8B-B5ED-3DAE9B49C425Q36724092-D2C830BE-3E86-4D01-97A4-25AC5C5B54A9Q36861597-1478DF69-2A40-4621-8F3D-0901A5329698Q36885522-72C42A1F-4638-4275-BB47-1EF1DD489A27Q36919780-6F0166C7-54EF-469C-A449-53BB24DEFB28
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Diana Giannarelli
@ast
Diana Giannarelli
@en
Diana Giannarelli
@es
Diana Giannarelli
@nl
Diana Giannarelli
@sl
type
label
Diana Giannarelli
@ast
Diana Giannarelli
@en
Diana Giannarelli
@es
Diana Giannarelli
@nl
Diana Giannarelli
@sl
prefLabel
Diana Giannarelli
@ast
Diana Giannarelli
@en
Diana Giannarelli
@es
Diana Giannarelli
@nl
Diana Giannarelli
@sl
P1053
T-5507-2017
P106
P21
P31
P3829
P496
0000-0002-6085-1195